Daewoong Pharmaceutical and CG Bio have launched a new animal medical device, BEARSOME, a transparent adhesive wound dressing for pets. This product expands Daewoong's portfolio following its development of an atopic treatment for dogs, marking a significant move into the pet healthcare market.
On July 1, Daewoong Pharmaceutical announced that BEARSOME has received product approval from the Animal and Plant Quarantine Agency and is now available in the domestic market.
BEARSOME is designed to protect the skin of pets with damaged barriers due to first-degree burns, dryness, or wounds, preventing contamination. It adheres closely to the affected area, forming a protective barrier while maintaining a moist environment for the wound. The product features stem cell culture fluid, which enhances its skin protection capabilities through exosomes and growth factors.
The product will be distributed to veterinary clinics nationwide through Daewoong Pet, a specialized pet healthcare subsidiary of Daewoong Pharmaceutical.
Park Seong-soo, CEO of Daewoong Pharmaceutical, stated, "BEARSOME is a product born from the combination of Daewoong's biotechnology and CG Bio's medical device development capabilities. We plan to continue developing products to expand treatment options for pets."
Meanwhile, Daewoong Pharmaceutical entered the animal pharmaceutical sector last year with the development of 'Enblo Pet' and is currently in discussions for technology exports with overseas animal medicine companies.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.